Blinatumoab公司
医学
不利影响
内科学
入射(几何)
细胞因子释放综合征
淋巴细胞白血病
白血病
疾病
光学
物理
传染病(医学专业)
2019年冠状病毒病(COVID-19)
作者
Anthony Selwyn Stein,Richard A. Larson,Andre C. Schuh,WILLIAM C. STEVENSON,Ewa Lech‐Marańda,Qui Tran,Zachary Franklin Zimmerman,William N. Kormany,Max S. Topp
出处
期刊:Blood Advances
[Elsevier BV]
日期:2018-06-28
卷期号:2 (13): 1522-1531
被引量:45
标识
DOI:10.1182/bloodadvances.2018019034
摘要
Key Points In the phase 3 TOWER study, exposure-adjusted AE rates were lower for blinatumomab vs SOC chemotherapy in Ph− B-cell r/r ALL patients. These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for B-cell r/r ALL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI